AFT Pharmaceuticals - H125 profitability weighed down by one-offs
AFT Pharmaceuticals has released a trading update ahead of its H125 results, expecting to report a c NZ$2m operating loss for the period ending...
190 Views
AFT Pharmaceuticals - Maxigesic IV reaches the Chinese shores
AFT Pharmaceuticals has taken another major step in extending its international footprint, with the signing of an exclusive license agreement for...
261 Views
AFT Pharmaceuticals - Hikma partnership expands to include Combogesic
AFT Pharmaceuticals has expanded its licensing partnership with Hikma in the US to include distribution of the recently launched Combogesic tablets...
332 Views
AFT Pharmaceuticals - Continued execution of footprint expansion
AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with...
169 Views
AFT Pharmaceuticals - Growth underpinned by international momentum
AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven...
241 Views